Skip to main content
Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia.
Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.
Clinical outcomes after 4.5?years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era.
Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.
Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Lifespan care in SCD: Whom to transition, the patients or the health care system?